SIRT3 and B-cell chronic lymphocytic leukemia: Several studies have described pharmacological approaches leading to SIRT3 activation, for the treatment of diseases associated with SIRT3 deficiency [45] and several aging-related conditions, such as type 2 diabetes, most persistent diseases of rheumatologic interest or chronic lymphocytic leukemia [45,46].